antares pharma welcomes robert p roche jr to board of directors  business wire antares pharma welcomes robert p roche jr to board of directors july    am eastern daylight time ewing njbusiness wireantares pharma inc nasdaq atrs today announced the election of robert p roche jr to the company’s board of directors mr roche has served as principal of robert roche associates llc a consulting firm providing guidance to the pharmaceutical and healthcare industries since february  from january  through february of  mr roche led commercial operations at cephalon inc a global biopharmaceutical company prior to his retirement from cephalon mr roche held the position of executive vice president worldwide pharmaceutical operations in which capacity he oversaw several successful new product launches leonard s jacob md phd chairman of the board of antares pharma stated “the addition of bob roche to our board is welcomed and timely his background and success in commercial operations and product launches will serve to complement the experienced sales and marketing team that antares has assembled subject to fda approval the company plans to launch otrexup™ for the treatment of rheumatoid arthritis early next year” “i am excited to be joining the board of antares pharma at this point in the company’s growth” said robert p roche jr “the company has developed a comprehensive commercialization plan for otrexup™ which i am confident will result in a wellcoordinated launch early next year the launch plan will also serve as a template for other drugdevice combination products in their pipeline such as qs t for testosterone replacement therapy” added mr roche mr roche was elected unanimously by the company’s board of directors at the recommendation of the nomination and governance committee before joining cephalon mr roche served as director and vice president worldwide strategic product development for smithkline beecham’s central nervous system and gastrointestinal products business prior to that he held senior marketing positions in canada and spain and had product planning responsibilities for smithkline in latin america mr roche began his pharmaceutical career in  with smithkline  french as a us pharmaceutical sales representative he is a graduate of colgate university and earned an mba from the wharton school at the university of pennsylvania paul k wotton phd president and chief executive officer stated “i am pleased to have someone with bob’s wide ranging experience join our board bob’s track record of success speaks for itself his extensive commercial and product launch experience will be invaluable as we continue to execute against our strategic plan and complete our transition to a specialty pharmaceutical company” about antares pharma antares pharma focuses on selfadministered parenteral pharmaceutical products and topical gelbased medicines the company is developing otrexup™ a combination product for the delivery of methotrexate using medijet™ technology for the treatment of rheumatoid arthritis polyarticularcourse juvenile rheumatoid arthritis and psoriasis as well as vibex™ qs t for testosterone replacement therapy the companys technology platforms include vibex™ disposable medijet™ disposable multiuse pen injectors and vision™ reusable needlefree injectors marketed as tjet® and zomajet® by teva pharmaceutical industries ltd teva and ferring pharmaceuticals ferring respectively antares pharma has a multiproduct deal with teva that includes tevtropin® human growth hormone hgh vibex™ epinephrine and several other products antares pharma’s partnership with ferring includes zomacton® hgh in the us antares has received fda approval for gelnique ™ a treatment for overactive bladder that is marketed by actavis elestrin® estradiol gel is fda approved for the treatment of moderatetosevere vasomotor symptoms associated with menopause and is marketed in the us by meda pharma antares pharma has two facilities in the us the parenteral products group located in minneapolis minnesota directs the manufacturing and marketing of the company’s reusable needlefree injection devices and related disposables and develops its disposable pressureassisted medijet™ and pen injector systems the company’s corporate office and product development and commercial groups are located in ewing new jersey safe harbor statement this press release contains forwardlooking statements within the meaning of the safe harbor provisions of the private securities litigation reform act of  these statements are indicated by the words “may” “will” “plans” “intends” “believes” “expects” “anticipates” “potential” “could” “would” “should” and similar expressions such forwardlooking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forwardlooking statements these risks and uncertainties include among others changes in revenue growth and difficulties or delays in the initiation progress or completion of product development in addition the otrexup™ and quickshot testosterone products referred to in this press release have not yet been approved by the fda and the commercialization of otrexup™ and quickshot testosterone are dependent on the company receiving fda approval of these products additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forwardlooking statements is contained in the risk factors section of the companys annual report on form k for the year ended december   and in the companys other periodic reports and filings with the securities and exchange commission the company cautions investors not to place undue reliance on the forwardlooking statements contained in this press release all forwardlooking statements are based on information currently available to the company on the date hereof and the company undertakes no obligation to revise or update these forwardlooking statements to reflect events or circumstances after the date of this press release except as required by law contacts antares pharma incjack howarthvice president corporate affairsjhowarthantarespharmacom contacts antares pharma incjack howarthvice president corporate affairsjhowarthantarespharmacom search advanced news search advanced news search log in sign up robert p roche jr executive profile  biography  bloomberg july    pm et pharmaceuticals company overview of aratana therapeutics inc snapshotpeople  overviewboard memberscommittees executive profile robert p roche jrdirector  aratana therapeutics incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background mr robert p roche jr also known as bob is the founder of robert roche associates llc mr roche served as an executive vice president of worldwide pharmaceutical operations at cephalon inc from february  to february   mr roche joined cephalon inc in january  and served as senior vice president of pharmaceutical operations from november  to february  he served as managing director of smithklines pharmaceutical operations in the philippines  mr roche served as senior vice president of sales and marketing of cephalon inc since june  and as vice president of sales and marketing he served as principal of robert roche associates llc since february  from january  to february  he served as the head of all commercial operations at cephalon inc he joined cephalon in january  and resigned in february  he has more than  years of international pharmaceutical industry experience he has extensive expertise in pharmaceutical product development commercialization and marketing his substantial experience in launching pharmaceutical products and his involvement in the development of public pharmaceutical companies make him a valuable member of nupathe inc mr roche served as director and vice president of worldwide strategic product development for smithkline beechams central nervous system and gastrointestinal products business he joined smithkline in  and in his career there held various senior marketing and management positions including several international assignments mr roche has been a director at aratana therapeutics inc since june  paragon bioservices inc since october   and civitas therapeutics inc since december  he has been an independent director of egalet corporation since december   and antares pharma inc since july  he also serves on the board of bryn mawr hospital mr roche served as an independent director of ekr therapeutics inc since october  until  he served as a director at nupathe inc since july  until  he served as a director of licecell inc until  he served as a director of intercept pharmaceuticals inc and civitas therapeutics of chelsea ma he served as an independent director of lifecell corporation from october   to may  mr roche holds ba in history and spanish from colgate university and master of business administration degree from the wharton school university of pennsylvaniaread full background corporate headquarters  tomahawk creek parkwayleawood kansas united statesphone fax  board members memberships presentdirectornupathe incpresentdirectorcivitas therapeutics incpresentindependent directorantares pharma incpresentdirector aratana therapeutics incpresentdirectorparagon bioservices incpresentindependent directoregalet corporation education ba colgate universitymba university of pennsylvania  the wharton school other affiliations cephalon inclifecell corporationantares pharma inccolgate universityuniversity of pennsylvania  the wharton schoolintercept pharmaceuticals incnupathe incekr therapeutics incparagon bioservices inccivitas therapeutics incegalet corporation annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation total annual cash compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationnamepositioncompanycompensationian d page chief executive officer managing director and executive directordechra pharmaceuticals plckjack clifford bendheim chairman chief executive officer and presidentphibro animal health corporationmmatthieu frechin chief executive officer and directorvétoquinol saklisa a conte chief executive officer president and directorjaguar animal health inckrobert t joseph president chief executive officer  directorparnell pharmaceuticals holdings ltdcompensation as of fiscal year  sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact aratana therapeutics inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close robert w roche  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in robert w roche board member at rvue holdings inc view full profile are you robert w roche claim your profile   sign up for equilar atlas and view robert w roches full profile with equilar atlas you can identify corporate executives in robert w roches network and community follow changes in robert w roches employment and moneyinmotion connect with robert w roche through your network of contacts robert w roches executive work history current board member rvue holdings inc past to view robert w roches complete executive work history sign up now age      robert w roches biography robert roche has served as a director of ours since march   he is an entrepreneur attorney and private equity investor and conducts numerous business operations throughout asia and the united states he is a cofounder and chairman of the board of directors of acorn international inc nyse atv a multiplatform media and branding company and one of the first companies in china to use tv direct sales programs often referred to as tv infomercials in combination with nontv direct sales platforms and a nationwide distribution network to market and sell consumer products he is also the cofounder and chairman of oak lawn marketing  read more robert roche has served as a director of ours since march   he is an entrepreneur attorney and private equity investor and conducts numerous business operations throughout asia and the united states he is a cofounder and chairman of the board of directors of acorn international inc nyse atv a multiplatform media and branding company and one of the first companies in china to use tv direct sales programs often referred to as tv infomercials in combination with nontv direct sales platforms and a nationwide distribution network to market and sell consumer products he is also the cofounder and chairman of oak lawn marketing one of the largest infomercial company in japan he has lived in japan and china for more than  years mr roche received his bachelors degree in economics and japanese studies from illinois state university in  and a jd degree from the university of denver in  mr roche was selected as a director because of his extensive experience in executive capacities with two large international corporations and his extensive experience in tv direct sales source rvue holdings inc on    sign up for equilar atlas and view robert w roches full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like robert w roche more specifically youll be able to identify corporate executives in robert w roches network and community follow changes in robert w roches employment and moneyinmotion connect with robert w roche through your network of conections view full profile   search for over  executive profiles bio example robert w roche robert w roches connections  sign up now to view robert w roches  connections » thomas l harrison board member zynerba pharmaceuticals inc mark pacchini former chief executive officer president and acting chief financial officer rvue holdings inc david a loppert former chief financial officer secretary and treasurer rvue holdings inc jay w wilson former chief technology officer rvue holdings inc dawn e rahicki former chief marketing officer rvue holdings inc peter emerson former board member rvue holdings inc michael f mullarkey former executive chairman of the board and chief executive officer rvue holdings inc jason m kates former consultant and former chief executive officer rvue holdings inc robert n chimbel former board member rvue holdings inc patrick j odonnell former chairman of the board president and chief executive officer histogenics popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla jan koum board member facebook inc philip l milstein board member the marcus corporation × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   antares pharma welcomes robert p roche jr to board of directors antares pharma welcomes robert p roche jr to board of directors tweet july     am pdt ewing nj business wire  antares pharma inc nasdaq atrs today announced the election of robert p roche jr to the company’s board of directors mr roche has served as principal of robert roche associates llc a consulting firm providing guidance to the pharmaceutical and healthcare industries since february  from january  through february of  mr roche led commercial operations at cephalon inc a global biopharmaceutical company prior to his retirement from cephalon mr roche held the position of executive vice president worldwide pharmaceutical operations in which capacity he oversaw several successful new product launches leonard s jacob md phd chairman of the board of antares pharma stated “the addition of bob roche to our board is welcomed and timely his background and success in commercial operations and product launches will serve to complement the experienced sales and marketing team that antares has assembled subject to fda approval the company plans to launch otrexup™ for the treatment of rheumatoid arthritis early next year” “i am excited to be joining the board of antares pharma at this point in the company’s growth” said robert p roche jr “the company has developed a comprehensive commercialization plan for otrexup™ which i am confident will result in a wellcoordinated launch early next year the launch plan will also serve as a template for other drugdevice combination products in their pipeline such as qs t for testosterone replacement therapy” added mr roche mr roche was elected unanimously by the company’s board of directors at the recommendation of the nomination and governance committee before joining cephalon mr roche served as director and vice president worldwide strategic product development for smithkline beecham’s central nervous system and gastrointestinal products business prior to that he held senior marketing positions in canada and spain and had product planning responsibilities for smithkline in latin america mr roche began his pharmaceutical career in  with smithkline  french as a us pharmaceutical sales representative he is a graduate of colgate university and earned an mba from the wharton school at the university of pennsylvania paul k wotton phd president and chief executive officer stated “i am pleased to have someone with bob’s wide ranging experience join our board bob’s track record of success speaks for itself his extensive commercial and product launch experience will be invaluable as we continue to execute against our strategic plan and complete our transition to a specialty pharmaceutical company” about antares pharma antares pharma focuses on selfadministered parenteral pharmaceutical products and topical gelbased medicines the company is developing otrexup™ a combination product for the delivery of methotrexate using medijet™ technology for the treatment of rheumatoid arthritis polyarticularcourse juvenile rheumatoid arthritis and psoriasis as well as vibex™ qs t for testosterone replacement therapy the companys technology platforms include vibex™ disposable medijet™ disposable multiuse pen injectors and vision™ reusable needlefree injectors marketed as tjet® and zomajet® by teva pharmaceutical industries ltd teva and ferring pharmaceuticals ferring respectively antares pharma has a multiproduct deal with teva that includes tevtropin® human growth hormone hgh vibex™ epinephrine and several other products antares pharma’s partnership with ferring includes zomacton® hgh in the us antares has received fda approval for gelnique ™ a treatment for overactive bladder that is marketed by actavis elestrin® estradiol gel is fda approved for the treatment of moderatetosevere vasomotor symptoms associated with menopause and is marketed in the us by meda pharma antares pharma has two facilities in the us the parenteral products group located in minneapolis minnesota directs the manufacturing and marketing of the company’s reusable needlefree injection devices and related disposables and develops its disposable pressureassisted medijet™ and pen injector systems the company’s corporate office and product development and commercial groups are located in ewing new jersey safe harbor statement this press release contains forwardlooking statements within the meaning of the safe harbor provisions of the private securities litigation reform act of  these statements are indicated by the words “may” “will” “plans” “intends” “believes” “expects” “anticipates” “potential” “could” “would” “should” and similar expressions such forwardlooking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forwardlooking statements these risks and uncertainties include among others changes in revenue growth and difficulties or delays in the initiation progress or completion of product development in addition the otrexup™ and quickshot testosterone products referred to in this press release have not yet been approved by the fda and the commercialization of otrexup™ and quickshot testosterone are dependent on the company receiving fda approval of these products additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forwardlooking statements is contained in the risk factors section of the companys annual report on form k for the year ended december   and in the companys other periodic reports and filings with the securities and exchange commission the company cautions investors not to place undue reliance on the forwardlooking statements contained in this press release all forwardlooking statements are based on information currently available to the company on the date hereof and the company undertakes no obligation to revise or update these forwardlooking statements to reflect events or circumstances after the date of this press release except as required by law filed in medical medical products pharmaceuticals science biotechnology research  development help us maintain quality content — report this story feed email pdf print contact antares pharma incjack howarthvice president corporate affairsjhowarthantarespharmacom more read more stories from antares pharma inc home  about  dlvrit social  browser extension  contact  api  help  tos add your story   robert roche  cephalon  inc  zoominfocom antares pharma welcomes robert p roche jr to board of directors  aol finance antares pharma welcomes robert p roche jr to board of directors share business wirevia the motley fool aolcom jul th  pm antares pharma welcomes robert p roche jr to board of directorsewing njbusiness wire antares pharma inc nas atrs today announced the election of robert p roche jr to the companys board of directorsmr roche has served as principal of robert roche associates llc a consulting firm providing guidance to the pharmaceutical and healthcare industries since february  from january  through february of  mr roche led commercial operations at cephalon inc a global biopharmaceutical company prior to his retirement from cephalon mr roche held the position of executive vice president worldwide pharmaceutical operations in which capacity he oversaw several successful new product launchesleonard s jacob md phd chairman of the board of antares pharma stated the addition of bob roche to our board is welcomed and timely his background and success in commercial operations and product launches will serve to complement the experienced sales and marketing team that antares has assembled subject to fda approval the company plans to launch otrexup™ for the treatment of rheumatoid arthritis early next yeari am excited to be joining the board of antares pharma at this point in the companys growth said robert p roche jr the company has developed a comprehensive commercialization plan for otrexup™ which i am confident will result in a wellcoordinated launch early next year the launch plan will also serve as a template for other drugdevice combination products in their pipeline such as qs t for testosterone replacement therapy added mr rochemr roche was elected unanimously by the companys board of directors at the recommendation of the nomination and governance committee before joining cephalon mr roche served as director and vice president worldwide strategic product development for smithkline beechams central nervous system and gastrointestinal products business prior to that he held senior marketing positions in canada and spain and had product planning responsibilities for smithkline in latin america mr roche began his pharmaceutical career in  with smithkline  french as a us pharmaceutical sales representative he is a graduate of colgate university and earned an mba from the wharton school at the university of pennsylvaniapaul k wotton phd president and chief executive officer stated i am pleased to have someone with bobs wide ranging experience join our board bobs track record of success speaks for itself his extensive commercial and product launch experience will be invaluable as we continue to execute against our strategic plan and complete our transition to a specialty pharmaceutical companyabout antares pharmaantares pharma focuses on selfadministered parenteral pharmaceutical products and topical gelbased medicines the company is developing otrexup™ a combination product for the delivery of methotrexate using medijet™ technology for the treatment of rheumatoid arthritis polyarticularcourse juvenile rheumatoid arthritis and psoriasis as well as vibex™ qs t for testosterone replacement therapy the companys technology platforms include vibex™ disposable medijet™ disposable multiuse pen injectors and vision™ reusable needlefree injectors marketed as tjet® and zomajet® by teva pharmaceutical industries ltd teva and ferring pharmaceuticals ferring respectively antares pharma has a multiproduct deal with teva that includes tevtropin® human growth hormone hgh vibex™ epinephrine and several other products antares pharmas partnership with ferring includes zomacton® hgh in the us antares has received fda approval for gelnique ™ a treatment for overactive bladder that is marketed by actavis elestrin® estradiol gel is fda approved for the treatment of moderatetosevere vasomotor symptoms associated with menopause and is marketed in the us by meda pharma antares pharma has two facilities in the us the parenteral products group located in minneapolis minnesota directs the manufacturing and marketing of the companys reusable needlefree injection devices and related disposables and develops its disposable pressureassisted medijet™ and pen injector systems the companys corporate office and product development and commercial groups are located in ewing new jerseysafe harbor statementthis press release contains forwardlooking statements within the meaning of the safe harbor provisions of the private securities litigation reform act of  these statements are indicated by the words may will plans intends believes expects anticipates potential could would should and similar expressions such forwardlooking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forwardlooking statements these risks and uncertainties include among others changes in revenue growth and difficulties or delays in the initiation progress or completion of product development in addition the otrexup™ and quickshot testosterone products referred to in this press release have not yet been approved by the fda and the commercialization of otrexup™ and quickshot testosterone are dependent on the company receiving fda approval of these products additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forwardlooking statements is contained in the risk factors section of the companys annual report on form k for the year ended december   and in the companys other periodic reports and filings with the securities and exchange commission the company cautions investors not to place undue reliance on the forwardlooking statements contained in this press release all forwardlooking statements are based on information currently available to the company on the date hereof and the company undertakes no obligation to revise or update these forwardlooking statements to reflect events or circumstances after the date of this press release except as required by lawantares pharma incjack howarthvice president corporate affairsjhowarthantarespharmacomkeywords   united states  north america  new jerseyindustry keywords the article antares pharma welcomes robert p roche jr to board of directors originally appeared on foolcom try any of our foolish newsletter services free for  days we fools may not all hold the same opinions but we all believe that considering a diverse range of insights makes us better investors the motley fool has a disclosure policycopyright     the motley fool llc all rights reserved the motley fool has a disclosure policy read full story cant get enough business news sign up for finance report by aol and get everything from retailer news to the latest ipos delivered directly to your inbox daily subscribe to our other newsletters emails may offer personalized content or ads learn more you may unsubscribe any time from our partners woman having a nice day at the beach narrowly escapes disaster why are we told to cook so many foods at  degrees people are freaking out about what baby flamingos actually look like the latest from our partners the fastest way to pay off your mortgage veterans could receive up to  with these va benefits crush your debt by refinancing to a  year fixed loan pay no interest until august  with this card rack up unlimited miles with this astonishing credit card an incredible  intro bonus just for using this card banks leaving money on the table – lock in rates now earn the money you deserve – compare top savings rates  cd rates that will skyrocket your finances owe less than k on your home dont miss this unique opportunity how to get a harp loan before it expires in september how to pay off your house asap easy tip  stores that are getting completely destroyed by amazon  crazy kitchen gadgets that are a complete waste of money the  most addicted cities behind the  billion opiate epidemic viral pic of nightmare jetblue passenger takes flight teen goes to metallica concert loses car for days cops  teens laugh and watch as man drowns recommended for youfamily says they were removed from flight after toddler kicked seatthe future is here and it may include robots taking your jobsmarketsusglobalscurrenciesdjianasdaqsp nikkei hang sengdaxusd per eurusd per chfjpy per usdgbp per usdall index data provided on a  minute delaymore to explorefrom our partnersphrases from obsolete technologyquick  dirty tipsthe best advice these  successful people ever receivedsuccess magazineshould you drink tap or bottled waterquick  dirty tipshow quickly can you expect to see muscle gainsquick  dirty tipshow to treat psoriasisquick  dirty tipsdo these  things if you want to become a leadersuccess magazineembrace the hustle with these  motivating quotessuccess magazineep  the problem with millennials issuccess magazineby pubexchange fri jul  °f set your location city state or zip change weather location mail search sign in  join my account log out news entertainment finance lifestyle games video shop ekr therapeutics announces robert p roche jr joins board of directors  business wire ekr therapeutics announces robert p roche jr joins board of directors october    pm eastern daylight time bedminster njbusiness wireekr therapeutics inc a privately held specialty pharmaceutical company focused on providing critical care products to the hospital marketplace has announced the appointment of robert p roche jr to the ekr board of directors as an independent director mr roche brings to ekr the experience of a distinguished career in the pharmaceutical industry prior roles include executive vice president worldwide pharmaceutical operations at cephalon inc as well as a general management role and several sales and marketing positions at smithkline beecham most recently mr roche served as principal of robert roche associates llc a consulting firm focusing on the pharmaceutical and biotechnology industries he served on the board of directors of intercept pharmaceuticals and lifecell corporation mr roche currently serves as independent director of nupathe inc located in conshohocken pa and serves as trustee of the westtown school “we are very privileged to add bob to our board he brings a wealth of operating and management experience to our company at a time when we are working hard to expand our business” says john bailye president and chief executive officer of ekr therapeutics about ekr therapeutics inc since its inception ekr has focused on acutecare hospital products and continues to actively pursue new opportunities in the hospital space with its experienced field force of sales professionals along with its commitment to excellence in customer service and medical education ekr is leading the way as a provider of acutecare specialty products for additional information about ekr visit the company’s website at wwwekrtxcom contacts ekr therapeutics incdoug petkus  release summary ekr therapeutics names new board member robert p roche jr contacts ekr therapeutics incdoug petkus  search advanced news search advanced news search log in sign up aratana therapeutics adds robert p roche jr to board of directors aratana therapeutics adds robert p roche jr to board of directors jun    et from aratana therapeutics inc kansas city kan june   prnewswire  aratana therapeutics inc nasdaq petx a pet therapeutics company focused on the licensing development and commercialization of innovative biopharmaceutical products for cats dogs and other companion animals today announced the appointment of former cephalon inc executive robert p roche jr to its board of directors  mr roche has extensive operational and product launch expertise working for leading pharmaceutical companies jay lichter phd chairman of the board of aratana therapeutics stated we are delighted to have mr roche join our board where he will also serve on the nominating and corporate governance committee  given his executive and board leadership expertise in the global pharmaceutical industry and his experience launching and commercializing new products we believe his insight and guidance will be invaluable to aratana mr roche remarked i am pleased to join aratana during this period of rapid growth as the company advances toward commercialization of its first products  i look forward to leveraging my background and expertise across aratanas deep pipeline of novel pet therapeutic candidates mr roche is the founder of robert roche associates llc a consulting firm providing guidance to pharmaceutical and healthcare companies  from  to  mr roche worked for cephalon inc serving most recently as executive vice president worldwide pharmaceutical operations since   prior to cephalon mr roche was director and vice president worldwide strategic product development for smithkline beechams central nervous system and gastrointestinal products business  in addition to serving as managing director of smithklines pharmaceutical operations in the philippines mr roche held senior marketing positions in canada and spain and had productplanning responsibilities for smithkline in latin america  mr roche serves as a director of antares pharma inc a publicly traded specialty pharmaceutical company and is currently a member of its governance and nominating committee and audit committee  mr roche is also a director of civitas therapeutics a privately held specialty pharmaceutical company  mr roche earned his ba from colgate university and his mba from the wharton school at the university of pennsylvania  about aratana therapeutics  aratana therapeutics is a pet therapeutics company focused on licensing developing and commercializing innovative biopharmaceutical products for cats dogs and other companion animals aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner the companys pipeline includes more than fifteen therapeutic candidates targeting pain inappetence cancer viral diseases allergy and other serious medical conditions  aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets medical needs safely and effectively resulting in longer and improved quality of life for pets  for more information please visit wwwaratanacom contacts for investor inquiries craig tooman chief financial officer ctoomanaratanacom   for media inquiries tiberend strategic advisors inc andrew mielach media amielachtiberendcom   source aratana therapeutics inc related links httpwwwaratanacom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more jul    et preview aratana therapeutics files for usda product license of at canine osteosarcoma immunotherapy jun    et preview aratana therapeutics to participate in two upcoming investor conferences my news release contains wide tables view fullscreen read more may    et aratana therapeutics to report second quarter  financial may    et aratana therapeutics to participate at three upcoming investment may    et aratana therapeutics reports first quarter  financial results looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search